Centene Q3 revenue tops estimates on Medicare growth

What happened

Centene reported third-quarter revenue that beat analyst estimates, helped by premium yield and membership growth in its Medicare Prescription Drug Plan business. Adjusted earnings per share also beat consensus, and the company raised its 2026 guidance.

Confirmed

Global impact / market context

More revenue and better-than-expected adjusted earnings mean Centene is taking in more money and managing costs well. That can support the share price because it shows the health insurer's core business is performing above what analysts expected.

Analyst inference

Analysts on average rate Centene shares a buy, with most recommending buy or hold and one sell. Their median 12-month price target sits above the October 26 closing price, suggesting modest expected upside.

Analyst inference

What to watch

1. Centene raised its 2026 adjusted diluted earnings per share guidance to greater than $5.20, signaling management expects stronger future profits for each share investors hold. Confirmed
2. Investors could compare Centene's lowered 2026 health benefits ratio guidance against future quarterly results, since this ratio shows the share of premium revenue spent on medical claims. Proposed
3. Watch whether Medicare membership growth and Marketplace pricing improvements continue, because these drove revenue and a lower health benefits ratio; a slowdown could pressure future revenue and profit. Analyst inference

Evidence

• Original source link unavailable